Answer ALS and Avanade harness technology to accelerate largest-ever ALS research program

Medical research centers, technology companies and 1,000 ALS patients unite in global collaborative search for new treatment protocols.

SEATTLE, December 10, 2019

The Answer ALS research program, a consortium of medical research centres, technology companies like Avanade, and 1,000 ALS patients, has completed phase one development of a massive technology infrastructure that could be a game-changer in the fight against ALS. The project will allow medical researchers around the world to securely collaborate in their search for the causes of ALS and develop new treatment protocols.

Answer ALS research, coordinated and driven by Johns Hopkins and the Robert Packard Centre for ALS Research, is the largest-ever ALS research effort. Its goal: achieve unseen levels of biological analysis by partnering with technology companies eager to stretch the boundaries of cloud computing, artificial intelligence (AI) and machine learning in a global search for ALS answers and treatments.

At the heart of Answer ALS is open collaboration and unimaginable amounts of data. The organisation worked with Avanade and other technology partners to build an extensive cloud-based research infrastructure that can not only securely accommodate trillions of bits of data, but also is designed to incorporate AI, machine learning and additional data as the project proceeds. This will allow Answer ALS to continue to take advantage of emerging technologies as its work progresses. One critical part of the infrastructure is a data query engine, developed by Avanade as part of its Technology for Social Good initiative, that allows researchers to submit a complicated research query and get an answer in hours rather than days or weeks.

Amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig’s disease, is a progressive motor neuron disease that slowly robs patients of their ability to move, speak and even, in the end, breathe. Researchers estimate there are as many as 400,000 ALS patients worldwide. About 5,600 people are diagnosed with ALS each year.

“Today we can interrogate cell function like never before,” said Emily Baxi, Ph.D., executive director of the Robert Packard Centre for ALS Research. “Answer ALS researchers are essentially building thousands of patient profiles, constructed piece by piece from multiple sources of data. Using the power of AI and machine learning to integrate and analyse these profiles, we hope Answer ALS will lay the groundwork for uncovering ALS patient subgroups and identify the most effective treatment strategies for each.”

“Avanade’s purpose is to make a genuine human impact,” said Avanade CEO Pam Maynard. “And what better way to do that than to help Answer ALS search for treatments, or even a cure for ALS? Our Avanade team is excited and honoured to work with this inspiring group of medical researchers, technology partners and patient participants.”

“If we truly want to have an impact on seemingly incurable diseases like ALS, Parkinson’s, Alzheimer’s and dozens of others, large scale, coordinated and collaborative efforts aided by technology are the best way to rapidly move forward,” said former NFL player Steve Gleason, an ALS patient himself, who now leads Team Gleason, a foundation instrumental in the formation of Answer ALS. “We haven’t answered ALS yet, but we are closer than ever before. Our work with technology partners like Avanade is a big reason for that.”

About Avanade

Avanade is the leading provider of innovative digital and cloud services, business solutions and design-led experiences on the Microsoft ecosystem. Our professionals bring bold, fresh thinking combined with technology, business and industry expertise to help make a human impact on our clients, their customers and their employees. We are the power behind the Accenture Microsoft Business Group, helping companies to engage customers, empower employees, optimise operations and transform products, leveraging the Microsoft platform. Avanade has 38,000 professionals in 25 countries, bringing clients our best thinking through a collaborative culture that honours diversity and reflects the communities in which we operate. Majority owned by Accenture, Avanade was founded in 2000 by Accenture LLP and Microsoft Corporation. Learn more at www.avanade.com.

About the Answer ALS Research Program

The Answer ALS research program was designed and implemented by Jeffrey Rothstein, M.D., Ph.D., founder and director of the Robert Packard Centre for ALS Research at Johns Hopkins. It was the direct result of a collaboration between the Packard Centre, other participating institutions, and Team Gleason, the organisation founded by former NFL player Steve Gleason after he was diagnosed with ALS. In 2014 Gleason and Team Gleason hosted a summit in New Orleans that brought together leading researchers, patients, caregivers and all ALS stakeholders for the first time in a single meeting. The call to action was to “think differently” and create a plan to ultimately end ALS in our lifetime.

The result was Answer ALS, now recognised as the single largest coordinated and collaborative ALS research project in the world. Under the leadership of the Packard Centre, nearly two dozen institutions, 1,000 patients and trillions of data points will be key to the project that Answer ALS believes could discover different types of ALS subgroups and develop customised treatment protocols that could allow patients to live vibrant, full lives.


Answer ALS and Avanade harness technology to accelerate largest-ever ALS research program

Medical research centers, technology companies and 1,000 ALS patients unite in global collaborative search for new treatment protocols.

Client Stories

Johns Hopkins and Answer ALS offer new hope to ALS patients

Avanade leads Azure project for Answer ALS.

Media Contacts


Dan DiPietro-James
+1 323 2520645


Phoebe Francis
+1 469 6802473

Share this page
Modal window